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Stereotactic body radiation therapy
a  b  s  t  r  a  c  t
Aim: To investigate whether the impact of dose escalation in our patient population repre-
sented an improvement in local control without increasing treatment related toxicity.
Materials and methods: A cohort of consecutive patients with colorectal liver metastases
treated with stereotactic body radiation therapy (SBRT) between December 2002 and
December 2013 were eligible for this study. Inclusion criteria were a Karnofsky performance
status ≥80% and, according to the multidisciplinary tumor board, ineligibility for surgery or
radiofrequency ablation. Exclusion criteria were a lesion size >6 cm, more  than 3 metastases,
and treatment delivered with other fractionation scheme than 3 times 12.5 Gy or 16.75 Gy
prescribed at the 65–67% isodose. To analyze local control, CT or MRI  scans were acquired
during follow-up. Toxicity was scored using the Common Toxicity Criteria Adverse Events
v4.0.
Results: A total of 40 patients with 55 colorectal liver metastases were included in this study.
We  delivered 37.5 Gy to 32 lesions, and 50.25 Gy to 23 lesions. Median follow-up was 26 and
25  months for these two groups. Local control at 2 and 3 years was 74 and 66% in the low
dose  group while 90 and 81% was reached in the high dose group. No significant difference
in  local control between the two dose fractionation schemes could be found. Grade 3 toxicity
was limited and was not increased in the high dose group.Conclusions: SBRT for colorectal liver metastases offers a high chance of local control at
long term. High irradiation doses may contribute to enhance this effect without increasingtoxicity.
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.  Background
iver metastases develop in up to 70% of patients with colorec-
al cancer. Resection is the ‘golden standard’ treatment with
eported median survival of 44 months and 34–40% of patients
eing alive at 5 years.1 Because most of the patients are
ot eligible for surgery, other nonsurgical ablation techniques
re used, with radiofrequency ablation (RFA) being the most
idely applied treatment modality. Several factors have been
escribed to impact the success rate of RFA. A tumor size >3 cm
as been identified as a predictor of a higher relapse rate.2 The
ocation of the tumors within the liver is also an important
actor; in particular tumors adjacent to large hepatic vessels
resent a unique problem due to the cooling effect provided
y the blood flowing through them.2 Location near the portal
ein pedicles is also associated with increased complications
ecause RFA in this area can cause injury to the main bile
uct resulting in biliary stricture.2 Retrospective RFA series for
olorectal liver metastases have shown site recurrence rates
f 9–42% for percutaneous RFA and 5–14% for open RFA with
edian survival of 36 months.3,4 For patients not eligible for
FA, stereotactic body radiation therapy (SBRT) offers the pos-
ibility to deliver potent biological doses to limited volumes of
he liver in a few fractions. High local control rates at 2 years of
4–91% and median survival of 34 months have been reported
fter SBRT for colorectal liver metastases.5,6
A few studies have assessed the role of dose escalation on
he clinical outcomes after SBRT for liver metastases. In 2006
ulf et al. found a significant improvement in 2 year local
ontrol (82 vs. 58%) with 12–12.5 Gy in 3 fractions or 26 Gy
n 1 fraction vs. 30 Gy in 3 fractions.7 No severe toxicity was
bserved. Later on, in a multi-institutional phase I/II study,
usthoven et al. evaluated the efficacy and tolerability of high
ose SBRT.8 The dose was safely escalated from 36 till 60 Gy
elivered in 3 fractions with 2 year local control rate of 92%.
nly one patient experienced grade III (soft tissue) toxicity.
ule et al. studied three dose-escalation cohorts and showed
 significant difference in local control between 60 Gy in 5 frac-
ions vs. 30 Gy in 3 fractions.9 No patient experienced grade III
r higher toxicity. Regardless of the above mentioned results,
autravers-Dewas and colleagues did not find a significant dif-
erence in local control between 40 Gy in 4 fractions and 45 Gy
n 3 for their cohort treated with SBRT.10
In 2010, our group reported a 2-year local control of 74%
or patients with colorectal liver metastases treated mainly
ith 37.5 Gy in 3 fractions.5 Later on, and based on published
ata, the dose was escalated to 50.25 Gy also delivered in 3
ractions. This retrospective study investigated whether the
ncrease in dose represented an improvement in local con-
rol without raising the treatment associated toxicity in our
atient population.
.  Materials  and  methods.1.  Design
his study was designed as a retrospective, observational, and
ingle institution. It was performed in accordance with thetherapy 2 2 ( 2 0 1 7 ) 126–131 127
code of ethics of the Helsinki declaration and approved by the
Ethical Committee of Erasmus Medical Center (MEC-2015-029).
2.2.  Population
All consecutive patients treated in our department between
December 2002 and December 2013 were considered can-
didates for this study. Patients should fulfill the following
criteria: diagnose of colorectal liver metastases, not eligible
for surgery or radiofrequency ablation (RFA) according to the
multidisciplinary tumor board, and a Karnofsky performance
score of at least 80%. If extrahepatic disease was present, it had
to be limited and potentially treatable with local therapies.
Exclusion criteria for this study included: a tumor diameter
>6 cm,  more  than 3 metastases per patient, and dose fraction-
ation scheme other than 3 times 12.5 Gy or 16.75 Gy delivered
at the 65–67% isodose.
2.3.  Endpoints
Primary endpoints of this study were the assessment of local
control and toxicity. Local control was defined as no in field
progression during follow-up on CT or MR  imaging. Toxic-
ity was scored with the Common Toxicity Criteria (CTC) of
the National Cancer Institute v 4.0. Secondary endpoint was
overall survival. Factors related to local control were also
investigated, including age, gender, and size and number of
metastases.
2.4.  Treatment  preparation  and  delivery
Between 2002 and 2011 patients were positioned in a stereo-
tactic body frame (Elekta Oncology Systems, Stockholm,
Sweden) with abdominal compression to reduce respiratory
tumor motion for planning and treatment purposes. Three
computed tomography (CT) scans per patient were acquired;
one in the arterial phase and one in the venous phase for
tumor definition, and one large-volume non-enhanced scan
for dose planning. Details about this procedure have been
reported earlier.5,11–13 From 2011, only one large contrast
enhanced planning CT in the venous phase was acquired.
The tumor delineations have always been reviewed by an
experienced radiologist. The boundary of the metastasis was
considered the border or contrast enhancement.
Since 2005, we have been implanting fiducial markers in
the vicinity of the tumor to assess the respiratory motion of
the area where the tumor is located. Initially the motion was
measured with video fluoroscopy registrations and later on
with a reconstruction of 4DCT registrations.14,15
No margin between gross target volume and clinical tar-
get volume was used. Planning target volume (PTV) margins
were initially based on the Karolinska experience.16,17 With
the introduction of fiducial markers, margins were individ-
ualized based on an in-house developed margin recipe that
was used to calculate required PTV margin for each patient
individually. The margin recipe takes as input the treatment
technique (e.g. tracking or non-tracking), the amplitude of
the respiratory-induced motion, and the distance between
the center-off-mass of the marker configuration and the cen-
ter of the tumor.15 For conventional linac based treatments
d radiotherapy 2 2 ( 2 0 1 7 ) 126–131
Table 1 – Demographics.
Patients 40
Gender ratio (M:F) 31:9
Median (range) age (years) 70 (35–86)
Patients with 1 metastasis 27
Patients with 2 metastases 11
Patients with 3 metastases 2
Metastases 55










Treatment with 3 × 12.5 Gy 32
Treatment with 3 × 16.75 Gy 23
Conventional linac vs. CyberKnife 40:15
Fig. 1 – Local control. Kaplan–Meier curves showing local
control over time.128  reports of practical oncology an
the personalized margins that were applied clinically ranged
between 8–10 mm superior–inferior, and 5–7 mm left–right and
anterior–posterior. For CyberKnife treatments the personal-
ized margins ranged between 5 and 7 mm in all directions.
The dose was prescribed at the periphery of the PTV. Planning
dose volume constraints for PTV and organs at risk have been
already published. Over time the liver constraint was modified
based on available new data.18
Until 2012 treatment was delivered with a conventional
linac and using a daily CT (not in room) and MV-or KV-imaging
for daily setup correction. Later on, the treatment was deliv-
ered with CyberKnife (Accuray, Sunnyvale, CA, USA), guided
by an incorporated real time fiducial tracking system using
KV imaging (Synchrony).
2.5.  Follow-up
Patients had a CT or MRI  scan at 1 month after irradiation and
every 3 months thereafter during the first two years. After this
period, imaging was performed every 6 months. Liver function
examinations were also performed including bilirubin, albu-
min  aspartate-and alanine amino transferases (AST and ALT),
gamma glutamyl tranferase (GGT), and alkaline phosphatase
(AF).
2.6.  Statistics
Descriptive statistics including mean, median, standard
deviation and range were calculated for each investigated
parameter. For categorical data, percentages per category were
calculated. To assess local control and survival, Kaplan–Meier
analyses were performed. We  also estimated the cumulative
incidence for local control with death as competing risk.19
The one-way ANOVA test was carried out to evaluate differ-
ences on tumor diameter between the low and the high dose
group. The Cox regression model was used to identify variables
associated with local control.
All data were analyzed with SPSS version 20 (Statistical
Package for the Social Sciences, Chicago IL) and the statistical
program R version 2.13 (http://www.R-project.org).
Statistical significance was considered p ≤ 0.05.
3.  Results
3.1.  Population
Between December 2002 and December 2013 we  treated 40
patients with 55 colorectal liver metastases that fulfilled the
inclusion and exclusion criteria. Gender distribution was 31
male and 9 female. Median age was 70 years. A total of 32
lesions with a median diameter of 2.7 cm (0.7–6.2) were treated
with 37.5 Gy, and 23 lesions with a median diameter of 2.2 cm
(0.9–4.2) were treated with 50.25 Gy. No significant difference in
diameter between the two groups was found (p = 0.3). Median
follow-up (imaging) was 26 months (1.5–80) for the low dose
group and 25 months (4.6–64) for the high dose group. Further
details are presented in Table 1.3.2.  Local  control
For the 37.5 Gy group the local control at 1, 2, and 3 years was
96, 74, and 66%, respectively. For the 50.25 Gy group, local con-
trol at 1, 2, 3 years was 90, 90 and 81%. See Fig. 1. No significant
difference could be found between the two dose fractionation
schemes (p = 0.44).
When analysing the local relapse incidence with the com-
peting risk method, the 1, 2 and 3 years in the low dose group
was 4, 18, and 23%. For the high dose group the values at 1,
2, and 3 years were 9, 9, and 16%. There was no significant
difference between the two groups (p = 0.41). See Fig. 2.
Univariate analysis showed that tumor diameter (>30 mm)
and number of lesions had a significant impact on local con-
trol. In multivariate analysis only the number of lesions was
significantly associated with local control (Table 2).
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Table 2 – Factors influencing local control. Univariate and multivariate analysis.






















HR: Hazard ratio, CI: Confidence interval, p: Probability value (significance)

















2 years were 74% after the delivery of 37.5 Gy and 90% after
50.25 Gy; however, this difference was not statistically signifi-
cant. Toxicity, as expected, remained limited.aplan–Meier test and the competing risk method.
.3.  Survival
verall survival at 1, 2 and 3 years in the group of patients
reated with 37.5 Gy was 95, 69 and 48%, respectively. In the
roup treated with 50.25 Gy it was 94, 81 and 65%. Median over-
ll survival in the low dose group was 35 months and in the
igh dose group was 43 months. The difference between the
wo groups was not significant (p = 0.46) (Fig. 3).
.4.  Toxicity
e  had no liver function investigations of five patients after
reatment. Two patients were followed in other hospitals and
hree were referred to other specialists just after SBRT. In one
atient we  did not perform any liver function investigation
efore treatment.Grade ≤2 hepatic toxicity was observed directly after SBRT
n all patients except one.
Two cases of grade 3 asymptomatic elevation of gamma
GT were found in the 37.5 Gy group. One case of grade 3–7.0)
.
GGT and aspartate transaminase elevation was detected in
the 50.25 Gy group.
One patient treated in the low dose group experienced
asthenia grade 3 with spontaneous recuperation two months
after treatment. Another patient developed grade 2 fat atrophy
and skin induration after SBRT for three subcapsular metas-
tases. As described in a previous paper, one patient developed
a portal hypertension syndrome with esophageal varices and
one episode of melena after two SBRT treatments.5,13 A case
of a biliary tree dilatation was observed in a patient treated for
a centrally located liver metastases with 50.25 Gy.
No case of grade 4 or 5 toxicity was observed.
4.  Discussion
This study corroborates a high chance of local control after
SBRT for colorectal liver metastases not eligible for other local
treatments, including surgery and RFA. Local control rates atFig. 3 – Overall survival. Kaplan–Meier curves showing
overall survival over time.
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Several papers have described a high local control rate after
SBRT for colorectal liver metastases. Recently, Scorsetti et al.
reported 2 and 3 year local control rates of 91 and 85% deliver-
ing 75 Gy in 3 fractions as a mean dose to the PTV in a similar
population to ours (1–3 lesions of <6 cm).6 Toxicity was limited
(no grade ≥3). Stintzing et al. reached a local control at 1 and
2 years of 87 and 55%, respectively, after 24 Gy delivered in 1
fraction in a group of patients with 1–2 metastases and <5 cm
diameter.20 No side effect was detected. Kim et al. observed a
local control chance of 60% at 2 and 3 years after 36–51 Gy in
3 fractions delivered at the 75–80% isodose.21 Patients had 1–3
liver metastases with total tumor volume of ≤500 ml.  No grade
≥3 complications were detected. Later on, Chang et al. after
a pooled analysis, estimated that a dose of 46–52 Gy (48 Gy)
was needed for a 1 year local control of >90%.22 In 2010, our
group reported a 74% local control rate at 2 years in a group of
patients treated mainly with 37.5 Gy delivered at the 65–67%
isodose surrounding the PTV.5 Two episodes of asymptomatic
elevation of GGT and one asthenia grade 3 were observed. In
our present series, 2 and 3 year local control rates were 74 and
66% for 37.5 Gy and 90 and 81% for 50.25 Gy. After correcting
for the risk of death, the chance of local relapse after these
two different schemes at 2 years was 18 and 9%, however, no
significant difference was found. Toxicity was not increased
in the high dose group.
A variety of relatively good results of local control at 2 years
between 50 and 91% for colorectal liver metastases after dif-
ferent SBRT fractionation schemes are presented above. Our
results fit very well in this range. It may be suggested that large
doses of irradiation are needed to ensure a high local control
at 2 and 3 years follow-up, and that this does not represent an
unsafe option.
The impact of dose escalation in the local control of liver
metastases has been published by several authors. In the
early years of SBRT, two German groups found a significant
improvement in local control related to dose escalation. The
investigators from Heidelberg observed that local control was
more  favorable after 26 Gy than after 14 Gy delivered in 1
fraction.23 The team from Wurzburg found a 2-year local con-
trol of 82 vs. 58% after delivering 36–37.5 Gy in 3 fractions or
26 Gy in 1 fraction vs. 30 Gy in 3 fractions.7 Later on, in the
North American multiinstitutional phase I/II study, the dose
was escalated from 36 to 60 Gy with reported 2 years local con-
trol rate of 92%. From the same authors group, a dose of at
least 54 Gy in 3 fractions had been proposed to achieve 89%
local control at 3 years for targets in lung and liver.24 Accord-
ingly, the authors from the University of Texas Southwestern
showed a significant difference in local control between 60 Gy
in 5 fractions and 30 Gy in 3 fractions (2 year 100 vs. 56%).8
However, not all groups have identified this significant rela-
tionship in their patient populations.10 In 2013, the American
Association of Physics in Medicine organized a working group
to quantitatively evaluate the impact of different dose frac-
tionation schemes in the local control of liver tumors.25 After a
PubMed search, 13 papers met  all inclusion criteria and formed
the dataset for the analysis. A significant relationship was
found between local control for liver metastases after SBRT
and a BED >100 Gy10. Although the BED of 37.5 Gy is <100 Gy10
and the BED of 50.25 Gy is >100 Gy10, we  have not found
this significant relationship in our population. A possibleiotherapy 2 2 ( 2 0 1 7 ) 126–131
explanation may be the lower number of metastases included
in our study compared with the AAPM (55 vs. 290).
The impact of tumor size on local control remains unclear.
In univariate analysis Rusthoven et al. showed a significant
difference for metastases of ≤3 cm vs. >3 cm (100 vs. 77%).8
No multivariate analysis was performed because of the small
number of events. Accordingly, we  also found the same result.
Chang et al. also showed in univariate analysis a significant
impact of tumor diameter on local control in a cohort of
colorectal liver metastases.22 However, Scorsetti et al. did not
observe this significant relationship.6 We did not find it either
in our first analysis published in 2010.5 Perhaps the fact that
the number of metastases in our last series has increased may
be the reason for this difference.
The number of metastases per patient has been found
significantly related to local control in our current analysis.
Thirteen patients had 2–3 metastases (8 received 37.5 Gy and
4 received 50.25 Gy). We  do not have a clear explanation for
this effect. A combination of factors such as tumor biology,
a deeper microscopic extension beyond the main metas-
tases border, size of the metastases and a higher number of
patients in the low dose group might have influenced this
finding.26
Due to the different patient selection criteria for SBRT, the
overall survival rates associated with different local treatment
techniques are difficult to compare, and therefore we  did not
consider overall survival as a primary endpoint of this study.
Nevertheless, our median survival seems comparable to the
recently published 36 months by Shady et al. after RFA for
colorectal liver metastases.3
A limitation of this study is the retrospective design. Also,
the number of patients is not large; however, it is comparable
with the ranges of most liver SBRT studies. The only way to
solve this problem is the collaboration of many  centers. In the
Netherlands a web based database will in the close future col-
lect the data of all patients with liver metastases treated with
SBRT from different institutions.
There are no randomized trials between SBRT and other
treatment techniques. In an attempt to compare RFA with
SBRT, Stintzing and colleagues evaluated the outcomes of
these two treatments in a single institution retrospective
study.27 The cohort included 60 heavily treated colorectal
cancer patients. Median SBRT dose was 24–26 Gy at the 80%
isodose. Local control at 1 and 2 years were not significantly
different but favored SBRT (85 vs. 65% and 80 vs. 61%). A sig-
nificant longer local-disease free survival was observed in the
SBRT group (34.4 vs. 6 months). No significant difference in
median overall survival was found although the difference
was almost significant (p = 0.06) with 52.3 vs. 34.4 months,
favoring RFA. The authors attribute this difference to a pos-
sible patient selection. The 2-year local control after SBRT
in our series fit well with the results found in the study.
Differences in median survival as mentioned by Stintzing
et al. are most probably due to patient selection in the two
studies.
We conclude that SBRT for colorectal liver metastases
offers a high chance of local control at long term in patients
that are not eligible for other local treatments including
surgery and RFA. High irradiation doses may contribute to
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